Bicara Therapeutics (NASDAQ:BCAX) Posts Earnings Results, Misses Estimates By $0.29 EPS

Bicara Therapeutics (NASDAQ:BCAX) posted its earnings results on Monday. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.29), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara says its pivotal FORTIFY-HN01 trial is on track for substantial enrollment by year-end, with an interim analysis planned in mid‑2027 to support potential accelerated approval of FICERA.
• Peer‑reviewed phase I‑B data (1,500 mg weekly + pembrolizumab) published in JCO showed deep, durable activity (median DOR 21.7 months; median OS 21.3 months) and the company will present 3‑year follow‑up across cohorts at ASCO.
• Bicara plans an alternative‑dosing randomized study (≈150–200 patients) starting in 3Q testing a 12‑week 1,500 mg weekly induction then either continued weekly or 2,250 mg every‑3‑weeks maintenance, with PFS as the primary endpoint to enable a more practical commercial regimen.
• Financially, the company ended Q1 with about $539.8M in cash and raised $161.8M (net) in February, providing runway into H1 2029, while warning operating expenses will rise as it funds the pivotal trial and builds commercial infrastructure.
• Management changes and commercial hires—Bill Schelman promoted to CMO and Alex Kharazi hired as CCO—signal preparations to transition from clinical stage to a commercial organization ahead of a potential launch.

Bicara Therapeutics Stock Performance

Shares of BCAX stock traded up $0.27 during trading hours on Monday, hitting $22.85. 288,996 shares of the company were exchanged, compared to its average volume of 510,427. The firm has a market cap of $1.50 billion, a P/E ratio of -9.03 and a beta of -0.57. Bicara Therapeutics has a fifty-two week low of $7.80 and a fifty-two week high of $24.25. The company has a 50 day simple moving average of $20.52 and a two-hundred day simple moving average of $17.99.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BCAX. Guggenheim began coverage on shares of Bicara Therapeutics in a report on Monday. They issued a “buy” rating and a $42.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Wells Fargo & Company increased their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Bank of America began coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price for the company. Finally, Citigroup began coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating for the company. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Insider Activity at Bicara Therapeutics

In other news, insider David Raben sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $22.88, for a total transaction of $125,840.00. Following the completion of the sale, the insider owned 55,286 shares of the company’s stock, valued at $1,264,943.68. This trade represents a 9.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00. Following the sale, the chief operating officer directly owned 196,141 shares of the company’s stock, valued at approximately $4,513,204.41. This trade represents a 5.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 174,310 shares of company stock worth $3,459,283.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently bought and sold shares of BCAX. T. Rowe Price Investment Management Inc. grew its position in Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares during the period. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics in the 4th quarter valued at $44,484,000. Vestal Point Capital LP grew its position in Bicara Therapeutics by 80.6% in the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after purchasing an additional 2,231,025 shares during the period. Franklin Resources Inc. acquired a new stake in Bicara Therapeutics in the 4th quarter valued at $27,265,000. Finally, State Street Corp grew its position in Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.